Evidence map›Paper›PMID 40640365›Full record

ArticleScientific reports2025

MSH6 as a prognostic biomarker in bladder cancer and its correlation with immunity.

Ning He, Lu-Ri Bao, Peng-Cheng Ma, Zhen-Li Fu, Wu-Niri Gao, Jing-Yuan Wang, Li-Gang Chen, Yan Meng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ning He *Department of Hemodialysis, The No. 2 Hospital of Hohhot, Hohhot, People's Republic of China.
Lu-Ri Bao *Department of Pathology, School of Basic Medicine, Inner Mongolia Medical University, Hohhot, People's Republic of China.
Peng-Cheng Ma *Department of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, People's Republic of China.
Zhen-Li FuDepartment of Hemodialysis, The No. 2 Hospital of Hohhot, Hohhot, People's Republic of China.
Wu-Niri GaoDepartment of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, People's Republic of China.
Jing-Yuan WangDepartment of Pathology, School of Basic Medicine, Inner Mongolia Medical University, Hohhot, People's Republic of China.
Li-Gang ChenDepartment of Urology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People's Republic of China.
Yan MengDepartment of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, People's Republic of China. mbao124@qq.com.

Funding

General Project of Inner Mongolia Natural Science Foundation No. 2022MS08063Inner Mongolia "Grassland Talents" Program Young Innovative Talent Project No. Q2022082Inner Mongolia Health Science and Technology Project in 2022 No. 202201293Key Research and Development and Achievement Transformation Project in the social welfare field of the 14th five-year plan in the Inner Mongolia Autonomous Region No. 2022YFSH0087Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences 2024GLLH0337Shanghai Key laboratory of Kidney and Blood Purification 14DZ226022Shanghai Key laboratory of Kidney and Blood Purification 20DZ2271600the National Natural Science Foundation of China No. 81960143the Trinity College Students Innovation and Entrepreneurship Cultivation Project of Inner Mongolia Medical University No. SWYT2020008
6 · The paper itself

Abstract

This study aims to investigate the role of MSH6 in the diagnosis and prognosis of bladder cancer and its association with immunity. Various analyses were conducted on The Cancer Genome Atlas (TCGA) data, and the results were validated using the Gene Expression Omnibus (GEO) database. The potential mechanism of MSH6 in bladder cancer was revealed using R tools, Gene Set Enrichment Analysis (GSEA), and Gene Ontology (GO) analysis. Bladder cancer patients admitted to the Affiliated Hospital of Inner Mongolia Medical University from June 2023 to December 2023 were enrolled. Pathological specimens of bladder cancer and adjacent tissues were obtained. Immunohistochemical results showed the expression of MSH6 in bladder cancer tissues was higher than in adjacent tissues. High expression of MSH6 was identified as an independent prognostic factor for bladder cancer. The occurrence of bladder cancer was also influenced by age, pathological T stage, and pathological stage. According to the Kaplan-Meier survival curve, the overall survival rate of the MSH6 high-expression group was lower (P = 0.004). After MSH6 was knocked down in cell experiments, the proliferation, colony formation, and migration abilities of bladder cancer cells were significantly inhibited. MSH6 is significantly associated with the diagnosis and prognosis of bladder cancer, suggesting its potential utility as a biomarker for these purposes. MSH6 is closely related to the tumor immune microenvironment, implying a significant role in immunotherapy.

Indexed as

Biomarkers, TumorDNA-Binding ProteinsUrinary Bladder NeoplasmsAgedCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisBiomarkers, TumorDNA-Binding ProteinsG-T mismatch-binding proteinBiomarkersBladder cancerBladder urothelial carcinomaImmunizationMSH6

Identifiers

PMID40640365
PMCPMC12246188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.